2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D(1) Receptor for Parkinson’s Disease

[Image: see text] Tolerance development caused by dopamine replacement with l-DOPA and therapeutic drawbacks upon activation of dopaminergic receptors with orthosteric agonists reveal a significant unmet need for safe and effective treatment of Parkinson’s disease. In search for selective modulators...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Cárceles, Javier, Vázquez-Villa, Henar, Brea, José, Ladron de Guevara-Miranda, David, Cincilla, Giovanni, Sánchez-Martínez, Melchor, Sánchez-Merino, Anabel, Algar, Sergio, Teresa de los Frailes, María, Roberts, Richard S., Ballesteros, Juan A., Rodríguez de Fonseca, Fernando, Benhamú, Bellinda, Loza, María I., López-Rodríguez, María L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511493/
https://www.ncbi.nlm.nih.gov/pubmed/36044544
http://dx.doi.org/10.1021/acs.jmedchem.2c00949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511493/
https://www.ncbi.nlm.nih.gov/pubmed/36044544
http://dx.doi.org/10.1021/acs.jmedchem.2c00949

Ejemplares similares